Thus, in the two tumor models that are resistant to anti–PD-1 therapy, we found that AAV-IL-27 local therapy and anti–PD-1 combination could induce complete tumor rejection or better tumor growth inhibition when a low dose of AAV-IL-27 was used. Here, IL27 is linked to neoplasm.